糖尿病黄斑水肿治疗策略的变化与面临的问题  

Advances in the treatment strategies of diabetic macular edema and the problems

作　　者：戴虹[1] 卢颖毅[1] Dai Hong;Lu Yingyi(Department of Ophthalmology,Beijing Hospital,National Center of Gerontology,Beijing 100730,China)

机构地区：[1]北京医院眼科国家老年医学中心,北京100730

出　　处：《中华眼底病杂志》2022年第1期6-9,共4页Chinese Journal of Ocular Fundus Diseases

基　　金：首都卫生发展科研专项(2020-2-4051)。

摘　　要：糖尿病黄斑水肿(DME)是引起视力障碍的常见病因。因视力收益上的明显优势,抗血管内皮生长因子(VEGF)药物已成为DME的首选方案。早期、强化抗VEGF药物治疗的基础上结合其他个体化治疗的方案,是目前DME治疗的主要策略。由于DME病情的复杂性和抗VEGF药物治疗的局限性,DME治疗仍面临诸多的问题和困难。优化治疗方案,加强病程管理,开发新药物,有望提高DME治疗疗效,维持患者收益的视力和视功能。Diabetic macular edema(DME)is one of the common causes of visual impairment.Anti-vascular endothelial growth factor(VEGF)has become the preferred therapy for DME because of significant visual improvement.Early and intensive anti-VEGF therapy combined with other individualized treatments are currently the main strategy for DME treatment.Considering the complexity of DME and limitations of anti-VEGF therapy,there are still many problems and difficulties in the treatment of DME.Optimizing treatment strategies,strengthening management of the clinical course and developing new drugs,could improve the efficacy and maintain the improvement of visual acuity and visual performance.

关 键 词：糖尿病视网膜病变 黄斑水肿 血管生成抑制剂 述评 

分 类 号：R774.5[医药卫生—眼科] R587.2[医药卫生—临床医学]